<div id="readability-page-1"><p>In a report released yesterday, David Toung from Argus Research maintained a Buy rating on Solventum Corporation. The company’s shares closed yesterday at $82.98.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Toung is a 5-star analyst with an average return of <span>9.7%</span> and a 64.60% success rate. Toung covers the Healthcare sector, focusing on stocks such as Charles River Labs, Humana, and Johnson &amp; Johnson.</p> <p>In addition to Argus Research, Solventum Corporation also received a Buy from TR | OpenAI – 4o’s Rosa Clinessa  in a report issued on December 7. However, yesterday, Wells Fargo maintained a Hold rating on Solventum Corporation (NYSE: SOLV).</p></div>

SOLV

<p>Argus Research's David Toung maintained a Buy rating on Solventum Corporation, with shares closing at $82.98. Toung, a 5-star analyst, has a 9.7% average return and a 64.60% success rate. Solventum also received a Buy from TR | OpenAI – 4o’s Rosa Clinessa, while Wells Fargo maintained a Hold rating.</p>

Argus Research Remains a Buy on Solventum Corporation (SOLV)